Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer

Cancer Research

Volumn 62, Issue 19, 2002, Pages 5405-5407

  Howe, Louise R ^a,c   Subbaramaiah, Kotha ^a,c   Patel, Jay ^c   Masferrer, Jaime L ^d   Deora, Aparna ^d   Hudis, Clifford ^e   Thaler, Howard T ^e   Muller, William J ^f   Du, Baoheng ^a   Brown, Anthony M C ^a,d   Dannenberg, Andrew J ^a,d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b PFIZER INC   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d Memorial Sloan Kettering Cancer Center ^*

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; ANTICARCINOGENIC AGENTS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; ISOENZYMES; MAMMARY NEOPLASMS, EXPERIMENTAL; MAMMARY TUMOR VIRUS, MOUSE; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RECEPTOR, ERBB-2; SULFONAMIDES;

EID: 0036792206     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Yarden, Y. Biology of HER2 and its importance in breast cancer. Oncology, 61 (Suppl. 2): 1-13, 2001.
2. Seshadri, R., Firgaira, F. A., Horsfall, D. J., McCaul, K., Setlur, V., and Kitchen, P. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J. Clin. Oncol., 11: 1936-1942, 1993.
3. Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., Baselga, J., and Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med., 344: 783-792, 2001.
4. Dannenberg, A. J., Altorki, N. K., Boyle, J. O., Dang, C., Howe, L. R., Weksler, B. B., and Subbaramaiah, K. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol., 2: 544-551, 2001.
5. Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L. K., and Levin, B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342: 1946-1952, 2000.
6. Williams, C. S., Mann, M., and DuBois, R. N. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene, 18: 7908-7916, 1999.
7. Subbaramaiah, K., Norton, L., Gerald, W., and Dannenberg, A. J. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. Evidence for involvement of AP-1 and PEA3. J. Biol. Chem., 277: 18649-18657, 2002.
8. Ristimaki, A., Sivula, A., Lundin, J., Lundin, M., Salminen, T., Haglund, C., Joensuu, H., and Isola, J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res., 62: 632-635, 2002.
9. Liu, C. H., Chang, S. H., Narko, K., Trifan, O. C., Wu, M. T., Smith, E., Haudenschild, C., Lane, T. F., and Hla, T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem., 276: 18563-18569, 2001.
10. Alshafie, G. A., Abou-Issa, H. M., Seibert, K., and Harris, R. E. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol. Rep., 7: 1377-1381, 2000.
11. Harris, R. E., Alshafie, G. A., Abou-Issa, H., and Seibert, K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res., 60: 2101-2103, 2000.
12. Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., and Muller, W. J. Expression of the neu proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA. 89: 10578-10582, 1992.
13. Siegel, P. M., Dankort, D. L., Hardy, W. R., and Muller, W. J. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell. Biol., 14: 7068-7077, 1994.
14. Siegel, P. M., Ryan, E. D., Cardiff, R. D., and Muller, W. J. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J., 18: 2149-2164, 1999.
15. Howe, L. R., Crawford, H. C., Subbaramaiah, K., Hassell, J. A., Dannenberg, A. J., and Brown, A. M. C. PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2. J. Biol. Chem., 276: 20108-20115, 2001.
16. Leahy, K. M., Ornberg, R. L., Wang, Y., Zweifel, B. S., Koki, A. T., and Masferrer, J. L. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res, 62: 625-631, 2002.
17. 2 that regulate cellular immune responses in the mouse. J. Clin. Investig., 108: 1229-1235, 2001.
18. Arakawa, T., Laneuville, O., Miller, C. A., Lakkides, K. M., Wingerd, B. A., DeWitt, D. L., and Smith, W. L. Prostanoid receptors of murine NIH 3T3 and RAW 264.7 cells. Structure and expression of the murine prostaglandin EP4 receptor gene. J. Biol. Chem., 271: 29569-29575, 1996.
19. Howe, L. R., Subbaramaiah, K., Brown, A. M. C., and Dannenberg, A. J. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr. Relat. Cancer, 8: 97-114, 2001.
20. Bennett, A., Berstock, D. A., Raja, B., and Stamford, I. F. Survival time after surgery is inversely related to the amounts of prostaglandins extracted from human breast cancers. Br. J. Pharmacol., 66: 451-455, 1979.
21. Narumiya, S., Sugimoto, Y., and Ushikubi, F. Prostanoid receptors: structures, properties, and functions. Physiol. Rev., 79: 1193-1226, 1999.
22. Soslow, R. A., Dannenberg, A. J., Rush, D., Woerner, B. M., Khan, K. N., Masferrer, J., and Koki, A. T. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer (Phila.), 89: 2637-2645, 2000.
23. 2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology, 137: 5739-5742, 1996.
24. Δ716 knockout mice. Nat. Med., 7: 1048-1051, 2001.
25. 1 antagonist, on breast cancer development. Carcinogenesis (Lond.), 22: 2001-2004, 2001.
26. Mann, M., Sheng, H., Shao, J., Williams, C. S., Pisacane, P. I., Sliwkowski, M. X., and DuBois, R. N. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology, 120: 1713-1719, 2001.